These results highlight the potential of RANKL inhibition to enhance the therapeutic efficacy of CDK4/6 inhibitors, offering a promising avenue for overcoming resistance and improving clinical outcomes in aBC. The gene discussed is CDK4; the disease is aneurysmal bone cyst.